GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Profitability Rank

BioVaxys Technology (BioVaxys Technology) Profitability Rank : 0 (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Profitability Rank?

BioVaxys Technology has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

BioVaxys Technology's Operating Margin % for the quarter that ended in Jul. 2023 was %. As of today, BioVaxys Technology's Piotroski F-Score is 3.


Competitive Comparison of BioVaxys Technology's Profitability Rank

For the Biotechnology subindustry, BioVaxys Technology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Profitability Rank distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Profitability Rank falls into.



BioVaxys Technology Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

BioVaxys Technology has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BioVaxys Technology's Operating Margin % for the quarter that ended in Jul. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jul. 2023 ) / Revenue (Q: Jul. 2023 )
=-0.425 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

BioVaxys Technology has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


BioVaxys Technology Profitability Rank Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (BioVaxys Technology) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.